Sure — the GLP-1 boom is in high dungeon, but a nearly 20% upside from here, in about a year?

That’s a pretty bold prediction.

But so it goes — with the market increasingly looking for high cash flow, and steady business prospects — in defensive industries like human health care / drugs / weight loss delivery mechanisms (clearly, much of the US 25 to 65 adult population is borderline overweight, or actually overweight). Tangerine 2.0 chaos has run its course — the market wants… predictability.

In any event, here’s the latest, via The Street:

…On Tuesday, one of JPMorgan’s most closely watched healthcare stock analysts, Chris Schott, who frequently covers Pfizer Inc. (PFE), Eli Lilly, and Teva Pharmaceutical Industries Ltd. (TEVA), gave investors something to pay attention to.

He set a new price target for Lilly that’s well above that of other Wall Street analysts. That says a lot about how far the obesity drug boom still has to run. For anyone holding the stock or thinking about it before the August earnings, Schott’s call is worth a closer look.

JPMorgan analyst Chris Schott lifted his price target on Eli Lilly to $1,400 from $1,300, keeping an Overweight rating on the shares, Yahoo Finance reported….

Now you know. Onward to live magic shows — at the vintage Chi-theater — this weekend… smile.

नमस्ते